Rosiglitazone and metformin fixed-dose combination provides superior glycaemic control compared to metformin and rosiglitazone monotherapies, and was well tolerated in drug-naive type 2 diabetes patients

被引：0

作者：

Chou, H ^{[1
]}

Rood, J ^{[1
]}

Biswas, N ^{[1
]}

Strow, L ^{[1
]}

Krebs, J ^{[1
]}

Parikh, S ^{[1
]}

Huang, C ^{[1
]}

Cobitz, AR ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, King Of Prussia, PA USA

来源：

DIABETOLOGIA | 2005年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

766

引用

页码：A278 / A279

页数：2

共 50 条

[1] Fixed-dose combination of rosiglitazone and glimepiride provides superior glycaemic control compared with glimepiride or rosiglitazone monotherapy in drug-naive individuals with type 2 diabetes mellitus
Chou, H. S.
Segiet, T.
Jones-Leone, A. R.
Palmer, J. P.
DIABETOLOGIA, 2006, 49 : 492 - 493
[2] Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
Rosenstock, J.
Rood, J.
Cobitz, A.
Biswas, N.
Chou, H.
Garber, A.
DIABETES OBESITY & METABOLISM, 2006, 8 (06): : 650 - 660
[3] Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control
Rosenstock, J.
Rood, J.
Cobitz, A.
Huang, C.
Garber, A.
DIABETES OBESITY & METABOLISM, 2006, 8 (06): : 643 - 649
[4] Effects of Rosiglitazone/Metformin Fixed-Dose Combination Therapy and Metformin Monotherapy on Serum Vaspin, Adiponectin and IL-6 Levels in Drug-Naive Patients with Type 2 Diabetes
Kadoglou, N. P. E.
Kapelouzou, A.
Tsanikidis, H.
Vitta, I.
Liapis, C. D.
Sailer, N.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2011, 119 (02) : 63 - 68
[5] Rosiglitazone (RSG) and glimepiride (GLIM) fixed-dose combination (FDC) provides superior glycemic control compared with GLIM and RSG monotherapies in drug-naive individuals with type 2 diabetes (T2DM)
Palmer, Jerry P.
Segiet, Thomas S. E.
Jones-Leone, Angela R.
Strow, Leanne J.
Chou, Hubert S.
DIABETES, 2006, 55 : A129 - A129
[6] Response to Pokharna and Kanna: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
Garber, A.
DIABETES OBESITY & METABOLISM, 2008, 10 (05): : 436 - 437
[7] Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet
Raskin, P.
Lewin, A.
Reinhardt, R.
Lyness, W.
DIABETES OBESITY & METABOLISM, 2009, 11 (09): : 865 - 873
[8] Rosiglitazone in combination with glibenclamide plus metformin is effective and well tolerated in Type 2 diabetes patients
Jones, N
Jones, T
Menci, L
Xu, J
Freed, M
Kreider, M
DIABETOLOGIA, 2001, 44 : A235 - A235
[9] Letter to the editor in reference to article titled: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
Pokharna, H.
Kanna, B.
DIABETES OBESITY & METABOLISM, 2007, 9 (06): : 914 - 914
[10] Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycemic control similar to a rosiglitazone/metformin fixed-dose combination tablet
Raskin, Philip
Hang, Yaming
Lyness, William
DIABETES, 2008, 57 : A596 - A596

← 1 2 3 4 5 →